Catalent enters AAV vector production agreement with IVERIC bio

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/krtiacanut)
(Image: Getty/krtiacanut)

Related tags: Viral vector, Production line, Clinical trial, Trial supply management, Clinical research, Catalent, Catalent pharma solutions

Catalent is producing AAV vectors for the preclinical and clinical trial supply of Iveric bio’s lead drug candidates.

Iveric bio, which focuses on the development of gene therapy solutions for orphan inherited retinal diseases, will work with Catalent Biologics subsidiary, Paragon Gene Therapy.

Catalent acquired Paragon for $1.2bn in May 2019, for the production of preclinical and clinical trial supply of adeno-associated viral (AAV) vectors.

Together, the companies will produce the AAV vectors needed for Iveric’s drug therapy products IC-100 and IC-200 as they move into the clinic. Clinical trials for IC-100 are expected to begin in 2020 and 2021 for IC-200.

IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa, and IC-200 for the treatment of BEST1 related retinal diseases, which will be entering Phase I/II clinical trials within the next two years.

A spokesperson for Catalent Biologics told us that through this deal, Iveric bio will have access to Paragon’s manufacturing capabilities and capacity at Catalent’s site in Baltimore, Maryland.

No financial terms have been disclosed.

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Planning Your First-In-Human Trial

Planning Your First-In-Human Trial

Altasciences | 15-Jul-2022 | Technical / White Paper

A first-in-human (FIH) clinical trial is a significant milestone in the development of a potential new drug. A successfully conducted FIH trial provides...

Related suppliers

Follow us

Products

View more

Webinars